Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients?

10:57 EDT 13 Jun 2018 | Pharmaceutical Technology

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer; little progress has been made toward its treatment in...
Read More...

The post Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients? appeared first on Pharmaceutical Technology.

More From BioPortfolio on "Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients?"